The First Affiliated Hospital of Dalian Medical University
Phase
Not applicable
Started
2025-06
Last updated
2025-04-30
Condition(s) studied
Atrial FibrillationPersistent Atrial Fibrillation
Investigational drug(s) / intervention(s)
Modified Maze ablation with PFAPVI only with PFA
Modified Maze ablation with PFA: Modified Maze ablation with PFA
PVI only with PFA: PVI only with PFA
Study summary
In radiofrequency (RF) ablation of persistent atrial fibrillation (PeAF), the additional linear ablation beyond pulmonary vein isolation (PVI) does not yield an reduce atrial arrhythmias recurrences.The goal of this clinical trial is to evaluate the efficiency of pulsed filed (PF) energy-based bi-atrial modified Maze ablation vs PF energy-based PVI of PeAF.
The main questions it aims to answer are:
Does PF energy effectively perform linear ablation in the left atrium? Does PFA-based bi-atrial modified Maze ablation significantly improve the success rate of PeAF ablation compared with PFA-based PVI?
Patients with PeAF who meet the criteria and undergo catheter ablation will be randomly assigned to the study group (PF-based bi-atrial modified Maze ablation group) and control group (PF-based PVI only) in a 1:1 ratio. All patients will received a 7-d Holter at 3-,6-,9-,12-month after the ablation. The primary endpoint is the freedom from documented atrial arrhythmia (AF/AFL/AT lasting for over 30 seconds) recurrence monitored by ECG, 7-day ambulatory ECG, or equivalent cardiac monitoring from 4th to 12th month after the procedure without taking I/III AADs.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients diagnosed with symptomatic PeAF at 18-75 years old who are eligible for the PFA procedure, and have any the following documentation, within 180 days of randomization of either: i. A 24-hour continuous ECG recording (from any regulatory cleared rhythm monitoring device) confirming continuous AF, OR ii. Two ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days，OR iii. physician note of persistent continuous AF for \> 7 days
* The duration of AF lasting ≥ 1 year
Exclusion Criteria:
* PaAF or PeAF with duration \< 1 year
* has received catheter ablation procedure for AF or atrial septal defect repair before enrollment
* left atrial diameter ≥55 mm or thrombosis in the left atrium
* eGFR\<30mL/min/1.73m2
* a history of cerebrovascular disease within the last three months (including stroke and transient ischemic attack)
* acute or severe systemic infection
* refused to participate in this trial; or those who have participated in other clinical drug trials within 3 months prior to enrollment
* congenital heart disease, thyroid dysfunction, severe hepatic insufficiency (Child-Pugh classification B-C), severe coagulation dysfunction (international normalized ratio \> 1.5 or partial activated prothrombin time prolonged by ≥ 10 seconds, or plasma prothrombin time prolonged by ≥ 3 seconds, or fibrinogen ≤ 1.5 g/L), or active bleeding
* pregnant women, breastfeeding women or women who plan to become pregnant during the study period, those who have a positive pregnancy test result during the screening period
* life expectancy \< 12 months
Primary outcome measure(s)
Freedom from atrial tachycardia during blanking period to Month 12 — during blanking period to Month 12 freedom of occurrence ≥ 30 sec of Atrial Fibrillation (AF), Atrial Flutter (AFL), atrial Tachycardia (AT); or any electrical cardioversion or re-ablation for AF, AFL, or AT; or any Class I or III AAD use
Trial sites (3)
Facility
City
Region
Status
Jiangsu Provincial Hospital
Nanjing
Jiangsu
First Affiliated Hospital of Dalian Medical University
Dalian
Liaoning
The Affiliated Hospital Of Medical School Of Ningbo University
Ningbo
Zhejiang
More The First Affiliated Hospital of Dalian Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.